Business · 29/08/2005

FDA Releases Draft Guidance on Impurities in Drug Products for Industry

The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommendations for reporting impurities in drug products, particularly those resulting from degradation, for submissions of abbreviated new drug applications (ANDAs) or supplements to support changes in drug substance synthesis or manufacturing processes.